Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
about
Bevacizumab in advanced lung cancer: state of the art.Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.Optimizing treatment in recurrent epithelial ovarian cancer.Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients.Clinical trials in gynecologic oncology: Past, present, and future.Update on relapsed ovarian cancer treatment: from new consensus to daily clinical practice.The roles of pathology in targeted therapy of women with gynecologic cancers.The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis.Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.The role of tumor microenvironment in resistance to anti-angiogenic therapy.Major clinical research advances in gynecologic cancer in 2017.Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.Changes in ovarian cancer survival during the 20 years before the era of targeted therapy.Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement.Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectivesRisk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trialsTargeting the Microenvironment in High Grade Serous Ovarian Cancer
P2860
Q38641871-758020E1-EB8F-44DB-8667-9B89BC3D853EQ41524271-D815F4EE-C4F7-4880-AA59-03038ACE5BF0Q41660578-5161ABCE-E08E-4304-97D6-B4CE46C52551Q46270437-3CE7C318-72C6-4931-B6E4-1607D741267AQ47306372-43E4CAC5-BF46-401B-BABC-E7744E920BFCQ47549019-14961276-079C-4CC2-8905-AF5B85F4AD40Q47685928-C2F05953-3C85-4F62-9F68-4086E92655F7Q47796770-55D069D1-2FF9-4400-8048-1670A487E7EEQ47903356-C40FCFBE-AD8E-4B8B-9355-5837D1663F29Q49645276-CD3EFE52-6232-4BF3-BA89-EE3DD4914AB6Q50129142-B09A3DBD-27C4-4BC0-BEDD-A68301E19D65Q50664932-3DFC4F0B-3907-4AE8-ABF9-4F0C5B5D2841Q52645823-ACC53BE1-B1BC-4B22-BD70-CFA95917D897Q54952356-A7145BE1-670D-44C0-9785-9F5EEC35002AQ55041688-D330576A-BBEA-492A-BA76-7C001E5556FCQ55366217-9D7F05F3-B271-44F8-9D72-FA26DF9F2B2BQ55493644-57215C25-602D-44EC-B541-D3CCE38DD1D6Q57174233-A168FAC1-B9F6-4AE2-A639-E5412E5C947FQ58729601-A38CBF22-8FF9-4204-B604-EEE489BD984DQ58789499-082D384C-BF81-4890-AC70-CD9C6480566B
P2860
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Bevacizumab and paclitaxel-car ...... el, randomised, phase 3 trial.
@en
type
label
Bevacizumab and paclitaxel-car ...... el, randomised, phase 3 trial.
@en
prefLabel
Bevacizumab and paclitaxel-car ...... el, randomised, phase 3 trial.
@en
P2093
P2860
P921
P1433
P1476
Bevacizumab and paclitaxel-car ...... el, randomised, phase 3 trial.
@en
P2093
Byoung-Gie Kim
David M O'Malley
Deborah K Armstrong
Helen Huang
Joan L Walker
John K Chan
Keiichi Fujiwara
Krishnansu S Tewari
Mark F Brady
Nick M Spirtos
P2860
P304
P356
10.1016/S1470-2045(17)30279-6
P577
2017-04-21T00:00:00Z